In this study, Seiden and colleagues
1
assessed the utility of genomic testing to risk stratify 63 Black men with prostate
cancer eligible for active surveillance (AS) at King's County Hospital Center, which
serves a predominantly under-represented minority population in Brooklyn. In 63% of
the cohort, genomic testing was discordant with initial risk stratification, with
28 men being reclassified to a higher National Comprehensive Cancer Network (NCCN)
risk category and this was independent of a pre-biopsy prostate specific antigen (PSA)
>10 ng/ml, abnormal digital rectal examination (DRE) and a high Prostate Imaging-Reporting
and Data System (PI-RADS) score. In addition, 12 men were reclassified to a lower
NCCN risk classification.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- NCCN Risk Reclassification in Black men with low and intermediate risk Prostate Cancer after genomic testing.Urology. 2021; (In press)
- Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.JAMA Netw Open. 2020; 3e2031349
- Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.JAMA Oncol. 2019; 5: 975-983
- A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.Eur Urol. 2014; 66: 550-560
- Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.J Clin Oncol. 2021; 39: 1660-1670
- Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.JAMA Oncol. 2021; 7: 52-58
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
